Ergocalciferol


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Familial hypophosphataemia, Vitamin D-resistant rickets
Adult: Dosage is individualised according to patient response and requirement. 12,000-500,000 IU daily. Alternatively, 10,000-60,000 IU daily may be given with phosphate supplements. Readjust dose as soon as clinical improvement is observed. Frequent serum Ca determination is recommended when high therapeutic doses are used.

Oral
Hypoparathyroidism
Adult: Dosage is individualised according to patient response and requirement. In combination with Ca supplements and/or IV parathyroid hormone or dihydrotachysterol: 50,000-200,000 IU daily. Readjust dose as soon as clinical improvement is observed.
Child: Same as adult dose.

Oral
Vitamin D deficiency
Adult: Dosage is individualised according to patient response and requirement. Prophylaxis: 400 IU daily. Treatment: 800 IU daily, may require higher doses in severe deficiency. Alternatively, 50,000 IU once weekly may be necessary. In patients with deficiency due to liver disease or malabsorption states: Up to 40,000 IU daily.
Chống chỉ định
Hypercalcaemia, metastatic calcification, evidence of vitamin D toxicity, hypervitaminosis D, abnormal sensitivity to toxic effects of vitamin D; malabsorption syndrome (unless dosed appropriately).
Thận trọng
Patient with heart disease or arteriosclerosis, renal calculi, hyperphosphataemia. Obese patients (BMI >30 kg/m2). Treatment guidelines may vary among individual products (refer to product-specific recommendations). Renal impairment. Children. Pregnancy and lactation.
Phản ứng phụ
Significant: Hypercalcaemia, soft tissue calcification, hypercalciuria, vitamin D toxicity.
Gastrointestinal disorders: Nausea, abdominal pain, vomiting, constipation.
General disorders and administration site conditions: Weakness.
Investigations: Increased serum creatinine, weight loss.
Metabolism and nutrition disorders: Anorexia, thirst.
Nervous system disorders: Headache.
Renal and urinary disorders: Polyuria, nocturia.
Monitoring Parameters
Monitor serum or urinary Ca and phosphorus concentrations, and BUN initially once or twice weekly then at regular intervals; renal function as clinically indicated. Perform bone X-ray every month until the condition is stabilised and corrected. Monitor for signs and symptoms of vitamin D toxicity.
Quá liều
Symptoms: Hypercalcaemia with anorexia, nausea, vomiting, constipation, diarrhoea, polyuria, nocturia, thirst, lassitude, headache, sweating, and vertigo. Management: Symptomatic and supportive treatment. In case of hypercalcaemia, discontinue treatment and initiate low Ca diet or generous fluid intake. May require hydration with IV saline solution in severe cases.
Tương tác
Mineral oil and colestyramine may interfere with the absorption of vitamin D. May cause hypercalcaemia with thiazide diuretics in hypoparathyroid patients. May reduce the efficacy with rifampicin and isoniazid. Metabolism may be increased by phenytoin. May increase the arrhythmogenic effects of cardiac glycosides.
Tác dụng
Description: Ergocalciferol is a provitamin. Its active metabolite stimulates the Ca and phosphorous absorption by the small intestine, increases secretion of Ca from bone to blood, and promotes renal tubule phosphate reabsorption.
Synonym: calciferol, vitamin D2.
Onset: 10-24 hours. Max effect: Approx 1 month (after daily doses).
Pharmacokinetics:
Absorption: Well absorbed from the small intestine.
Distribution: Crosses the placenta and enters breast milk. Distributed in fat, muscle, skin and bones.
Metabolism: Metabolised in the liver by vitamin D 25-hydroxylase via hydroxylation to form 25-hydroxyergocalciferol; further metabolised in the kidneys by vitamin D 1-hydroxylase to active 1,25-dihydroxyergocalciferol.
Excretion: Via faeces; urine (small amounts).
Đặc tính

Chemical Structure Image
Ergocalciferol

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 5280793, Ergocalciferol. https://pubchem.ncbi.nlm.nih.gov/compound/Ergocalciferol. Accessed Oct. 26, 2020.

Bảo quản
Store between 15-30°C. Protect from light.
Phân loại MIMS
Phân loại ATC
A11CC01 - ergocalciferol ; Belongs to the class of vitamin D and analogues. Used as dietary supplements.
References
Anon. Ergocalciferol. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 15/09/2020.

Anon. Ergocalciferol. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 01/07/2020.

Buckingham R (ed). Vitamin D Substances. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/07/2020.

Calciferol Capsules (British Dispensary Health Care). MIMS Thailand. http://www.mims.com/thailand. Accessed 15/09/2020.

Drisdol Capsule, Liquid Filled (Validus Pharmaceuticals LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 05/07/2020.

Ergocalciferol Injection BP 300,000 U (RPH Pharmaceuticals AB). MHRA. https://products.mhra.gov.uk/. Accessed 05/07/2020.

Ergocalciferol Liquid (Virtus Pharmaceuticals). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 15/09/2020.

Ergocalciferol, Vitamin D2. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com/. Accessed 15/09/2020.

Joint Formulary Committee. Ergocalciferol. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 15/09/2020.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Ergocalciferol từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Frencerol
  • Infadin
  • Uvestérol D
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in